Ocena wpływu amisulprydu na grupy tiolowe osocza w modelu in vitro

(1)

247

"

Ocena wpływu amisulprydu na grupy tiolowe osocza w modelu in vitro

The assessment of amisulpride effects in vitro on plasma thiol groups

D > R @ ;*2/(H<4F*"%")H/*;*F"($2/* * @ @ @ * !24'4)G2* %+/(4$%* 4'(4)G+$* +1G+* GF4%/2&#4($* [* +1$* %$)"'(* 3$'$#G+4"'* G'+4&%.)1"+4)* [* ("$%* '"+* )G/%$* G'.* 4')#$G%$* *

(2)

248 **#$%&'()*%#'$**

7

)14H"&1#$'4)*&G+4$'+%*$T&$#4$')$*"T4(G+4J$*%+#$%%* G'(*&#"@"T4(G+4J$*&#")$%%$%ND@AO %$)"'(*3$'$#G+4"'*G'+4&%.)1"+4)%*;$#$*/%/G22.*($%)#4B$(* NE@D=O₉ -'*"/#*";'*%+/(.*4'* *F"($2*;$*1GJ$*$%+GB24%1$(*+1G+* )$#+G4'*%$)"'(*3$'$#G+4"'*G'+4&%.)1"+4)%*4'*)"')$'+#G+4"'%* G)+*&#"@"T4(G+4J$2.*"#*$J$'*)G/%$*G*(#/3@)"')$'+#G+4"'@($@ &$'($'+*($)#$G%$*4'*&2G%FG*24&4(*&$#"T4(G+4"'NEO_{9*74F42G#2.8*} 4'* ND=O_{9*U";$J$#8*'"*%/)1*} %+/(4$%*1GJ$*'"+*B$$'*)G##4$(*"/+*;4+1*GF4%/2&#4($8*G'(*'"* @ @ +#"2NDCO @ NDS@>?O₉ @ @ (4+4"'%8* 1/FG'*&2G%FG*24&4(*&$#"T4(G+4"'8*F$G%/#$(*B.*+1$*2$J$2%* @

5

@ @ ND@AO _@ @ @ @ NE@D=O₉ @ @ @ NEO_{9*0"("B'4$*;*BG(G'4G)1*} _! ND=O _@ NDCO _@ @ @ NDS@>?O₉ ;*F"($2/* @ @ @ @ @ *\F4%/2&#4($*4'*)"')$'+#G+4"'*

(3)

249

@ N>?O_9*0#H$&#"@ ;G(H"'"*BG(G'4G*4'+$#'4%+.)H'$8*'$/#"2"34)H'$*4*2GB"#G+"@ @ @ @ @ @ @ '.)1*N'G#<"+.<P;8*G2<"1"2/8*'4<"+.'.O8*'4$*%/&2$F$'+";G@ @ @ @ @

)

@ @ @ 3G'$F/*&"*;4$2"<#"+'.F*HG%+"%";G'4/*(G;$<*%+"%"@ @ @ @ @ N>DO _@ N>>O₉

)

;*"%")H/*4'</B";G'.F*>Q*3"(H4'.*H*GF4%/2&#.($F*4*(2G* NF$G'*G3$*>=b?9C*.$G#%O9*M1$*&G+4$'+%K*F$'+G2*1$G2+1*;G%* @ &%.)14G+#4)*-'+$#J4$;N>?O_{9*M1$.*/'($#;$'+*4'+$#'G28*'$/#"@}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

)

@ @ @ Z"#*$G)1*$T&$#4F$'+*+1$*)"'+#"2*%GF&2$%*;$#$*FG($8*)"'%4%+@ @ +4"'*G'(*)"'+#"2*%GF&2$%*;$#$*+$%+$(*%&$)+#"&1"+"F$+#4)G2@ @ N>DO N>>O₉ @

(4)

250

H*;.<"#H.%+G'4$F*<;G%/*=8=K@(4+4"B4%@N>@'4+#"B$'H"$%";$@ @ '4G*BG#;'$3"*(4G'4"'/*<;G%/*=@+4"@>@'4+#"B$'H"$%";$3"* λ N>DO _@ @ ε @D @D_O9* @ @ N>RO _@ '4G*+4"24*;.<"'G'"*;*(;/<#"+'.)1*&";+P#H$'4G)19 @ @ @ ;$3"*NML\O*;*?8>=*6*U!29*0#PB.*F4$%HG'"*4*"3#H$;G'"* @ @ @ @ @ ε =_*6@D @D @ @

%3%21#%)-0%0$-0$,#3%

@ @ @ @ @ #P;'G'4/*H*&#PBGF4*<"'+#"2'.F48*'4$*;.;4$#G*4%+"+'$3"* +#"2*%GF&2$%*;4+1"/+*+1$*+$%+$(*(#/38*;$#$*F$G%/#$(*G))"#(@ @ FGT4FG2*GB%"#BG')$*G+*λ N>DO_{9*M1$*+"+G2*+14"2%*)"')$'@} ε @D @D_O9*M1$*"B@ +G4'$(*#$%/2+%*;$#$*$T&#$%%$(*G%*+14"2%*)"')$'+#G+4"'*&$#*F4224@ @ %$#/F*G2B/F4'*%"2/+4"'*;G%*/%$(*G%*G*%+G'(G#(N>RO_{9*M1$*+14"2%*} )"')$'+#G+4"'*F$G%/#$F$'+%*;$#$*FG($*4'*(/&24)G+$9

)

@ @ +14"BG#B4+/#4)*G)4(*NML\O*4'*?9>=*6*U!29*M1$*%GF&2$%*;$#$* F$G%/#$(*/%4'3*D*)F*+14)<*)/J$++$*G+*λ Nε =_*6@D @D _@ @ &#4($9*M1$*F$G%/#$F$'+%*;$#$*FG($*4'*(/&24)G+$9*M1$*)"'@

-0%01-01,%2)%3%2$-1-@ +4%+4)G2*G'G2.%4%,*G#4+1F$+4)*F$G'%*G'(*%+G'(G#(*($J4G+4"'* @ @ @ G%*)"F&G#$(*+"*+1$*)"'+#"2*%GF&2$%8*)G/%$(*G'*4')#$G%$* @ @

(5)

251

;*&"&#H$('4"*&#";G(H"'.)1*BG(G'4G)1O*4%+"+'.*%&G($<* @ @ '.)1*+4"24*;*"%")H/9 @ @ Stężenie amisulprydu

Concentration of amisulpride Marker Kontrola (bez leku)Control (without drug) AmisulprydAmisulpride p

n=10 n=10

278 ng/ml Tiole [nmol/mg białka]

Thiols [nmol/mg of protein] Mean valueŚrednia 2,8024 2,8773 p>0,05

SEM 0,1012 0,0753

Tiole [μmol/l]

Thiols [μmol/l] Mean valueŚrednia 0,1299 0,1332 p>0,05

SEM 0,0047 0,0037

578 ng/ml Tiole [nmol/mg białka]

Thiols [nmol/mg of protein] Mean valueŚrednia 2,8024 2,9227 p<0,03

SEM 0,1012 0,0728

Tiole [μmol/l]

Thiols [μmol/l] Mean valueŚrednia 0,1299 0,1355 p<0,03

SEM 0,0047 0,0035 0,26 0,24 0,22 0,20 0,18 0,16 0,14 0,12 0,10 0,08 0,06 0,04 0,02 0,00 110 100 90 80 70 60 50 40 30 20 10 0 % Amisulpryd 278 ng/ml

Amisulpride 278 ng/ml Amisulpryd 578 ng/mlAmisulpride 578 ng/ml

St

ęż

enie w

oln

ych tioli [nmol/mg bia

łka] Conc entr ation of fr ee thiols [nmol/mg of pr otein] p>0,05* p>0,05* p<0,03* p<0,003* ! ! ! !

* Względem kontroli, sparowany test t-Studenta. * In relation to control, paired Student t-test.

p – różnica względem kontroli (wartości bezwzględne), sparowany test t-Studenta.

p – difference in relation to the control (absolute values), paired Student t-test. Kontrola bez leku

Control without drug Amisulpryd 278 ng/ml

Amisulpride 278 ng/ml Amisulpryd 578 ng/ml

(6)

252 ',-.#/$#/

@ @ @ +4"24ONDA8DE8>Q8>=O _@ @ F")H";.N>C8>SO @ N>A8>EO_{9*^F4G'.*B4"FG#<$#P;*%+#$%/*"<%.(G@} @ %&#H$)H'$NR?O NRDO_*"#GH* "F$3G@R*;*"%")H/NR>8RRO₉ @ @ @ @ @ @ @ @ @ NRQO @ @ @ @ @ @ NR=O₉ @ @ @ @ &%.)1"+.)H'.)1ND8>8Q@C8A8>=O "T4(G+4J$*%+#$%%*G'(*#$2G+$(*24&4(*&$#"T4(G+4"'*G%*;$22*G%* @ @ 2G#*G'+4"T4(G'+%8*4')2/(4'3*+14"2%ONDA8DE8>Q8>=O_{9*7"F$*G/+1"#%*} @ G'(*/#4)*G)4(N>C8>SO_{9*Z/#+1$#F"#$8*4'*%)14H"&1#$'4)*&G+4$'+%*} +"*B$*($)#$G%$(N>A8>EO _@ @ @ @ #.NR?O _@ NRDO_* G)4(%*4'*&2G%FGNR>8RRO₉ 4'(/)$(*B.*JG#4"/%*(#/3%8*4')2/(4'3*G'+4&%.)1"+4)%8*"'*"T@ @ (4%"#($#%8*"'*+1$*"#3G'4%FK%*3$'$+4)G22.*)"'(4+4"'$(*)G@ G%*G'+4"T4(G+4J$*$'H.F$%*"#*2";@F"2$)/2G#*G'+4"T4(G'+%8* @ 32/+G+14"'$8*).%+$4'$8*1"F").%+$4'$*G'(*3GFFG@32/+GF@ .2).%+$4'$NRQO _@ 4'*&#"+$4'%*&2G.%*G'*4F&"#+G'+*#"2$*4'*+1$*FG4'+$'G')$* @ 3#"/&%*4'*&#"+$4'*F"2$)/2$%NR=O₉ @ @ @ ND8>8Q@C8A8>=O_{9*-'*G((4+4"'8*} %+/(4$%*"'*G'4FG2*F"($2*;G%*($%)#4B$(NDD8DQ8D=O 4'(4)G+$*+1G+*GF4%/2&#4($8*

(7)

253

@ ;$F*'4$<+P#.)1*2$<P;*&#H$)4;&%.)1"+.)H'.)1*;*BG(G@ NDD8DQ8D=O @ @ @ NDRO _@ N7UO*;*"%")H/N>QO @ \F4%/2&#.(*;*(G;<G)1*#$<"F$'(";G'.)1*("*2$)H$'4G* @ @ F$(4)G+$(*G'(*F$(4)G+$(*%)14H"&1#$'4G*&G+4$'+%9*L4"29*0%.)14@ G+#.*>??RW*=R,*=C@CQ9 CQ,*QCE@QS=9 >??EW*D?,*>S@RR9 >??=W*DC,*RAC@RED9 @ @ @ @ @ +#.*>??RW*>S,*QRD@QQ?9 @ @ 4'*)"')$'+#G+4"'%*)"##$%&"'(4'3*+"*+1$*("%$%*#$)"FF$'(@ @ @ $+*G29NDRO_{*\%*4'*%)14H"&1#$'4)*&G+4$'+%*+1$*24&4(*&$#"T4(G+4"'*} 4%*#$(/)$(N>QO @ )"F4+G'+*;4+1*"T4(G+4J$*%+#$%%9 @ 4(*&$#"T4(G+4"'9 ;*"%")H/*[*BG(G'4G* >RS@>QC9 >??RW*RS,*QR@=D9 @ @ @ @ @ @ '"2*)"F&"/'(%*"'*24&4(*&$#"T4(G+4"'*)G/%$(*B.*G'+4&%.)1"+4)%* @ @ @ @ %/&29*>?,*>>@RR9

(8)

254

@ &$'B$#3*09U9*N#$(9O,*:GB"#G+"#.*M$)1'4V/$%*4'*L4")1$F4%+#.* DESEW*ER,*EA@D?>9 @ +$4'@(.$*B4'(4'39*\'G29*L4")1$F9*DESCW*S>,*>QA@>=Q9 DSS,*DA@>D9 QD,*C=>@C=A9 @ A?,*>E@RE9 @ $&4%"($*%)14H"&1#$'4)*&G+4$'+%9*L6!*0%.)14G+#.*>?DDW*DD,*D>Q9 @ @ @ ($&#$%%4"'*G'(*+1$4#*&"%%4B2$*)"'+#4B/+4"'*+"*+1$*N'$/#"O($3$'@ L4"29*0%.)14G+#.*>?DDW*R=,*CSC@CE>9 @ @ ($%&4+$*G&&G#$'+2.*G($V/G+$*+#$G+F$'+*;4+1*%+G'(G#(*(#/3%9* @ \F4'"*\)4(%*>??RW*>=,*R>R@RRE9 @